Effects of once ‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials

In conclusion, dulaglutide treatment of clinical trial participants with T2D did not affect eGFR and slightly decreased albuminuria.

Source: Diabetes, Obesity and Metabolism - November 23, 2016 Category: Endocrinology Authors: Katherine R. Tuttle, T. Dwight McKinney, Jaime A. Davidson, Greg Anglin, Kristine D. Harper, Fady T. Botros Tags: BRIEF REPORT Source Type: research